thalidomide has been researched along with AL Amyloidosis in 23 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the first phase 3 study in relapsed/refractory AL amyloidosis (TOURMALINE-AL1 NCT01659658), 168 patients with relapsed/refractory AL amyloidosis after 1-2 prior lines were randomized to ixazomib (4 mg, days 1, 8, 15) plus dexamethasone (20 mg, days 1, 8, 15, 22; n = 85) or physician's choice (dexamethasone ± melphalan, cyclophosphamide, thalidomide, or lenalidomide; n = 83) in 28-day cycles until progression or toxicity." | 9.51 | A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. ( Berg, D; Comenzo, RL; Dispenzieri, A; Faller, DV; Kastritis, E; Kim, K; Kumar, A; Kwok, F; Landau, HJ; Liu, G; Merlini, G; Sanchorawala, V; Schönland, SO; Suzuki, K; Wechalekar, AD, 2022) |
| "We designed a trial using two sequential cycles of modified high-dose melphalan at 100 mg/m(2) and autologous SCT (mHDM/SCT) in AL amyloidosis (light-chain amyloidosis, AL), AL with myeloma (ALM) and host-based high-risk myeloma (hM) patients through SWOG-0115." | 9.17 | Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115. ( Barlogie, B; Dean, RM; Fennessey, SA; Finn, KT; Hoering, A; Holmberg, LA; Mattar, B; Orlowski, RZ; Safah, HF; Sanchorawala, V; Seldin, DC; Sexton, R, 2013) |
| "Pomalidomide demonstrated activity in the treatment of AL amyloidosis in three phase II clinical trials." | 7.96 | Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients. ( Basset, M; Foli, A; Hegenbart, U; Kimmich, C; Mahmood, S; Merlini, G; Milani, P; Nuvolone, M; Palladini, G; Sachchithanantham, S; Schönland, SO; Sharpley, F; Wechalekar, A, 2020) |
| "Bortezomib and lenalidomide are increasingly used in patients with AL amyloidosis, but long term data on their use as primary therapy in AL amyloidosis are lacking while early mortality remains significant." | 7.81 | Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. ( Dimopoulos, MA; Gavriatopoulou, M; Kalapanida, D; Kaldara, E; Kastritis, E; Migkou, M; Ntalianis, A; Pamboucas, C; Psimenou, E; Roussou, M; Tasidou, A; Terpos, E; Toumanidis, ST, 2015) |
| "Patients with AL amyloidosis and low bone marrow plasma cell count generally undergo the harvest of hematopoietic cells from peripheral blood, followed by high-dose chemotherapy immediately after they are diagnosed." | 6.49 | [Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials]. ( Adam, Z; Cermáková, Z; Král, Z; Krejčí, M; Pour, L; Sčudla, V, 2013) |
| "In the first phase 3 study in relapsed/refractory AL amyloidosis (TOURMALINE-AL1 NCT01659658), 168 patients with relapsed/refractory AL amyloidosis after 1-2 prior lines were randomized to ixazomib (4 mg, days 1, 8, 15) plus dexamethasone (20 mg, days 1, 8, 15, 22; n = 85) or physician's choice (dexamethasone ± melphalan, cyclophosphamide, thalidomide, or lenalidomide; n = 83) in 28-day cycles until progression or toxicity." | 5.51 | A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. ( Berg, D; Comenzo, RL; Dispenzieri, A; Faller, DV; Kastritis, E; Kim, K; Kumar, A; Kwok, F; Landau, HJ; Liu, G; Merlini, G; Sanchorawala, V; Schönland, SO; Suzuki, K; Wechalekar, AD, 2022) |
| "Lenalidomide can be a good treatment option for AL amyloidosis in HIV-infected patients on antiretroviral therapy." | 5.46 | Lenalidomide as a treatment for relapsed AL amyloidosis in an HIV-positive patient. ( Cook, M; Denman, J; Manavi, K, 2017) |
| "We designed a trial using two sequential cycles of modified high-dose melphalan at 100 mg/m(2) and autologous SCT (mHDM/SCT) in AL amyloidosis (light-chain amyloidosis, AL), AL with myeloma (ALM) and host-based high-risk myeloma (hM) patients through SWOG-0115." | 5.17 | Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115. ( Barlogie, B; Dean, RM; Fennessey, SA; Finn, KT; Hoering, A; Holmberg, LA; Mattar, B; Orlowski, RZ; Safah, HF; Sanchorawala, V; Seldin, DC; Sexton, R, 2013) |
| "Pomalidomide demonstrated activity in the treatment of AL amyloidosis in three phase II clinical trials." | 3.96 | Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients. ( Basset, M; Foli, A; Hegenbart, U; Kimmich, C; Mahmood, S; Merlini, G; Milani, P; Nuvolone, M; Palladini, G; Sachchithanantham, S; Schönland, SO; Sharpley, F; Wechalekar, A, 2020) |
| "Chemotherapy regimen based on bortezomib and thalidomide had achieved hematologic partial remission, but the kidney had no response and psoriasis was still active." | 3.88 | Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report. ( Chen, W; Huang, X; Ren, G; Zuo, K, 2018) |
| "Bortezomib and lenalidomide are increasingly used in patients with AL amyloidosis, but long term data on their use as primary therapy in AL amyloidosis are lacking while early mortality remains significant." | 3.81 | Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. ( Dimopoulos, MA; Gavriatopoulou, M; Kalapanida, D; Kaldara, E; Kastritis, E; Migkou, M; Ntalianis, A; Pamboucas, C; Psimenou, E; Roussou, M; Tasidou, A; Terpos, E; Toumanidis, ST, 2015) |
| "Pomalidomide is a next-generation immunomodulatory agent with activity in relapsed light chain (AL) amyloidosis, but real world outcomes are lacking." | 2.87 | Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis. ( Gilmore, J; Hawkins, P; Lachmann, H; Mahmood, S; Manwani, R; Sachchithanantham, S; Sharpley, FA; Wechalekar, A; Whelan, C, 2018) |
| "Systemic AL amyloidosis is a protein-misfolding disorder that is characterized by the deposition of insoluble amyloid fibrils derived from kinetically unstable light chains." | 2.66 | Emerging drugs for the treatment of light chain amyloidosis. ( Chakraborty, R; Lentzsch, S, 2020) |
| "In conclusion, GI perforation in AL amyloidosis is rare and mostly reported after treatment initiation." | 2.58 | Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy - a case series and review of the literature. ( Avivi, I; Cohen, Y; Duek, A; Gatt, ME; Leiba, M; Shaulov, A, 2018) |
| "Patients with AL amyloidosis and low bone marrow plasma cell count generally undergo the harvest of hematopoietic cells from peripheral blood, followed by high-dose chemotherapy immediately after they are diagnosed." | 2.49 | [Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials]. ( Adam, Z; Cermáková, Z; Král, Z; Krejčí, M; Pour, L; Sčudla, V, 2013) |
| "Multiple myeloma (MM) and AL amyloidosis are caused by the expansion of monoclonal plasma cells and secretion of dysproteinemia (Bence Jones protein and free light chain) and some patients require the hemodialysis." | 2.48 | Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion. ( Suzuki, K, 2012) |
| "Patients with AL amyloidosis who need second-line therapy after response to up-front treatment generally have a good outcome." | 1.48 | Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. ( Basset, M; Foli, A; Merlini, G; Milani, P; Palladini, G; Perlini, S; Russo, F, 2018) |
| "Lenalidomide can be a good treatment option for AL amyloidosis in HIV-infected patients on antiretroviral therapy." | 1.46 | Lenalidomide as a treatment for relapsed AL amyloidosis in an HIV-positive patient. ( Cook, M; Denman, J; Manavi, K, 2017) |
| "Primarye systemic AL amyloidosis is a rare hematologic disorder." | 1.46 | [Treatment of systemic AL amyloidosis: about 25 cases]. ( Baaj, ME; Doghmi, K; Eddou, H; Maaroufi, HE; Mikdame, M; Moudden, MK; Zinebi, A, 2017) |
| "However, the impact of immunoparesis in AL amyloidosis has not been addressed." | 1.43 | Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis. ( Cohen, A; Iakobishvili, Z; Itchaki, G; Kornowski, R; Magen, H; Muchtar, E; Raanani, P; Rosenfeld, R; Shochat, T, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 19 (82.61) | 24.3611 |
| 2020's | 4 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| Jo, G | 1 |
| Shin, DY | 1 |
| Mun, JH | 1 |
| Milani, P | 2 |
| Sharpley, F | 1 |
| Schönland, SO | 3 |
| Basset, M | 2 |
| Mahmood, S | 2 |
| Nuvolone, M | 1 |
| Kimmich, C | 2 |
| Foli, A | 2 |
| Sachchithanantham, S | 2 |
| Merlini, G | 3 |
| Wechalekar, A | 2 |
| Palladini, G | 2 |
| Hegenbart, U | 2 |
| Chakraborty, R | 1 |
| Lentzsch, S | 1 |
| Dispenzieri, A | 1 |
| Kastritis, E | 2 |
| Wechalekar, AD | 1 |
| Kim, K | 1 |
| Sanchorawala, V | 2 |
| Landau, HJ | 1 |
| Kwok, F | 1 |
| Suzuki, K | 2 |
| Comenzo, RL | 1 |
| Berg, D | 1 |
| Liu, G | 1 |
| Kumar, A | 1 |
| Faller, DV | 1 |
| Prince, HM | 1 |
| Bochtler, T | 1 |
| Benner, A | 1 |
| Becker, N | 1 |
| Kristen, AV | 1 |
| Beimler, J | 1 |
| Hund, E | 1 |
| Zorn, M | 1 |
| Freiberger, A | 1 |
| Gawlik, M | 1 |
| Goldschmidt, H | 1 |
| Hose, D | 1 |
| Jauch, A | 1 |
| Ho, AD | 1 |
| Denman, J | 1 |
| Manavi, K | 1 |
| Cook, M | 1 |
| Russo, F | 1 |
| Perlini, S | 1 |
| Shaulov, A | 1 |
| Avivi, I | 1 |
| Cohen, Y | 1 |
| Duek, A | 1 |
| Leiba, M | 1 |
| Gatt, ME | 1 |
| Eddou, H | 1 |
| Zinebi, A | 1 |
| Maaroufi, HE | 1 |
| Moudden, MK | 1 |
| Doghmi, K | 1 |
| Mikdame, M | 1 |
| Baaj, ME | 1 |
| Joseph, NS | 1 |
| Kaufman, JL | 1 |
| Sharpley, FA | 1 |
| Manwani, R | 1 |
| Lachmann, H | 1 |
| Gilmore, J | 1 |
| Whelan, C | 1 |
| Hawkins, P | 1 |
| Arnall, JR | 1 |
| Usmani, SZ | 1 |
| Adamu, H | 1 |
| Mishkin, J | 1 |
| Bhutani, M | 1 |
| Chen, W | 1 |
| Ren, G | 1 |
| Zuo, K | 1 |
| Huang, X | 1 |
| Liu, B | 1 |
| Wang, Y | 1 |
| Bai, M | 1 |
| Wang, D | 1 |
| Zhao, J | 1 |
| Zhang, M | 1 |
| Sun, S | 1 |
| Adam, Z | 1 |
| Sčudla, V | 2 |
| Krejčí, M | 1 |
| Cermáková, Z | 1 |
| Pour, L | 1 |
| Král, Z | 1 |
| Hoering, A | 1 |
| Seldin, DC | 1 |
| Finn, KT | 1 |
| Fennessey, SA | 1 |
| Sexton, R | 1 |
| Mattar, B | 1 |
| Safah, HF | 1 |
| Holmberg, LA | 1 |
| Dean, RM | 1 |
| Orlowski, RZ | 1 |
| Barlogie, B | 1 |
| Pika, T | 1 |
| Lochman, P | 1 |
| Vymětal, J | 1 |
| Metelka, R | 1 |
| Minařík, J | 1 |
| Látalová, P | 1 |
| Zapletalová, J | 1 |
| Bačovský, J | 1 |
| Roussou, M | 1 |
| Gavriatopoulou, M | 1 |
| Migkou, M | 1 |
| Kalapanida, D | 1 |
| Pamboucas, C | 1 |
| Kaldara, E | 1 |
| Ntalianis, A | 1 |
| Psimenou, E | 1 |
| Toumanidis, ST | 1 |
| Tasidou, A | 1 |
| Terpos, E | 1 |
| Dimopoulos, MA | 1 |
| Muchtar, E | 1 |
| Magen, H | 1 |
| Itchaki, G | 1 |
| Cohen, A | 1 |
| Rosenfeld, R | 1 |
| Shochat, T | 1 |
| Kornowski, R | 1 |
| Iakobishvili, Z | 1 |
| Raanani, P | 1 |
| Charliński, G | 1 |
| Wiater, E | 1 |
| Jedrzejczak, WW | 1 |
| Sher, T | 1 |
| Hayman, SR | 1 |
| Gertz, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Single Center Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With AL Amyloidosis[NCT00883623] | Phase 2 | 50 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Comparison of Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy With or Without Doxycycline in Newly Diagnosed Mayo Stage II-III Light Chain Amyloidosis Patients: A Multi-center Randomized Controlled Trial[NCT03401372] | 140 participants (Actual) | Interventional | 2018-04-21 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for thalidomide and AL Amyloidosis
| Article | Year |
|---|---|
Emerging drugs for the treatment of light chain amyloidosis.
Topics: Animals; Antibodies, Monoclonal; Bridged Bicyclo Compounds, Heterocyclic; Drug Development; Humans; | 2020 |
Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy - a case series and review of the literature.
Topics: Adult; Aged; Bortezomib; Humans; Immunoglobulin Light-chain Amyloidosis; Intestinal Perforation; Len | 2018 |
Novel Approaches for the Management of AL Amyloidosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Boron Compounds; Glycine; Humans; Immunog | 2018 |
[Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].
Topics: Amyloidosis; Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Humans; Immunoglobulin Light-chain | 2013 |
Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.
Topics: Aged; Amyloidosis; Bence Jones Protein; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; | 2012 |
4 trials available for thalidomide and AL Amyloidosis
| Article | Year |
|---|---|
A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cyc | 2022 |
Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Huma | 2017 |
Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Immunoglobulin Light-chain Am | 2018 |
Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Dexamet | 2013 |
14 other studies available for thalidomide and AL Amyloidosis
| Article | Year |
|---|---|
Systemic amyloidosis-induced nail dystrophy.
Topics: Anti-Inflammatory Agents; Biopsy, Needle; Dermoscopy; Dexamethasone; Drug Therapy, Combination; Fema | 2019 |
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients.
Topics: Aged; Anti-Inflammatory Agents; Dexamethasone; Drug Resistance; Europe; Female; Follow-Up Studies; H | 2020 |
A cautionary tale of the use of lenalidomide and dexamethasone for relapsed/refractory immunoglobulin light chain (AL) amyloidosis.
Topics: Dexamethasone; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Lenalido | 2021 |
Lenalidomide as a treatment for relapsed AL amyloidosis in an HIV-positive patient.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; HI | 2017 |
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Chemotherapy, Adjuvant; Dexametha | 2018 |
[Treatment of systemic AL amyloidosis: about 25 cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Surviv | 2017 |
Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
Topics: Adult; Antibodies, Monoclonal; Cyclophosphamide; Dexamethasone; Female; Heart Failure; Hematopoietic | 2019 |
Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report.
Topics: Antineoplastic Agents; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin L | 2018 |
Cyclophosphamide + Thalidomide + Dexamethasone Versus Melphalan + Dexamethasone for the Treatment of Amyloid Light-chain Amyloidosis With Kidney Involvement: A Retrospective Study in Chinese Patients.
Topics: China; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light-chain Amyloidosis; Immunosuppre | 2019 |
[Attainment of complete hematological remission is crucial for extended survival of AL amyloidosis patients with cardiac involvement].
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclop | 2013 |
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response | 2015 |
Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis.
Topics: Aged; Aged, 80 and over; Amyloidosis; Bortezomib; Disease-Free Survival; Female; Humans; Immunoglobu | 2016 |
[Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
Topics: Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Combinations; Drug The | 2012 |
Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; | 2012 |